StockData
Passage BIO, Inc. logo

Passage BIO, Inc. (PASG) income statement

PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.13−0.08 (-2.01%)

Close on Nov 18, 2026Market cap $13.31MP/E –Yield –

Passage BIO, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-113.8%

Financial strength

Current ratio
1.22
Debt to equity
–
Debt to assets
–
Cash to current liabilities
116.6%

Valuation

P/E ratio
–
Price to sales
–
Price to book
2.99
Dividend yield
–

See a number that looks wrong?